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• Phase 1 & 2, US 
& Mali









• Transmission Blocking Vaccine





− Ookinete surface protein
− Produced in P. pastoris
− ± HIS6 fusion tag
• Pvs25
• Bio-assay: Membrane feeding
Clinical development, TBV
• CSP
− Sporozoite surface protein
− Produced in Pichia pastoris 
and in E. coli
Pre-clinical development, 
pre-erythrocytic vaccine
TBV: Pfs25 is a Lead Candidate
• Recombinant Pfs25 (& Pvs25) 
consistently induces functional 
antisera assessed by 
membrane feeding assay
• TB activity observed using 
purified IgG, with or without 
complement
• Human serum antibodies 
against Pfs25 demonstrate TB 
activity 





• Swiss outbred mice
• Immunized protein on Alum IM on D0 & D28













Transmission Blocking Activity 
in Mouse Sera
Pfs25 Pfs25-EPA
% Inhibition of oocyst 
count
55.7 99.3 














In process and bulk
• Appearance
• AAA
• Absorbance 280 nm
• AFM
• BCA













In-house reference: MV1351 cGMP lot
Comparison of Bulk Pfs25-EPA 
Conjugates
Reverse-phase HPLC analysis
cGMP lot, Mw = 545 kDa, Rh= 12.3 nm













bsorbance at 280 nm




− Deposition 10 min.
on clean mica in 
PBS
Analysis of Pfs25-EPA conjugate by AFM






Phase 1 malaria 
exposed adults 
Phase 1 malaria 
exposed children











Approaches to Improve TBV Efficacy
• Combine with other target antigen(s)
– CSP (pre-erythrocytic)
– Pfs230 (TBV)






• Identify suitable CS protein construct
– No HIS tag
– Scalable process
– Compatible with conjugation strategies
• Two forms of recombinant CSP produced
– AN87606 (India Strain)
• E. coli full length without signal sequence and GPI anchor 
plus HIS6 tag
• P. pastoris near full-length with and without free thiol
– NP473175 (3D7)






recombinant P. pastoris CSP
Plassmeyer et al., 2009 JBC 284:26951 
Recombinant PpCSP
1 x 25-30 nm
Region I
Coomassie blue stained SDS-PAGE gels
PpCSP M2 PpCSP M2C
NRNR R R
1 5 1 5 1 5 1 5 µg
Enhanced CSP immunogenicity:
CRM197 conjugate, GLA/SE adjuvant
Mice immunized on D0 and D28
Summary
• cGMP pilot-scale production of Pfs25-EPA 
successful
• Analytical parameters qualified for testing of bulk 
substance
• Formulation development for Pfs25-EPA 
ongoing
• Human phase 1 trial planned for 1qtr 2011
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